China's EV Makers Are Facing a Reality Check in Southeast Asia
On a recent Thursday morning in Hanoi, Chinese electric vehicle giant BYD Co. began the day with a showroom devoid of customers. Just a few kilometers away, a dealership for upstart Vietnamese EV maker VinFast Auto Ltd. was buzzing, with would-be buyers pouring over new models.
'We see an average of 20 customers every day during weekdays,' said Tran Trung Hieu, a VinFast salesman in black suit and tie. 'That can double or triple on a weekend.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
33 minutes ago
- Axios
China now owns 20% of global ad market
China's booming digital economy has boosted its share of the global ad market, challenging the United States' long reign as the world's largest ad market. China's 20% share of the global ad market is now greater than the country's share of global GDP, according to WPP Media. Why it matters: Chinese ad sellers are finding enormous success selling ads to audiences globally, especially in the U.S. But U.S. tech giants are still largely banned from China. By the numbers: Nine of the world's top 25 ad sellers today are Chinese, including TikTok-parent ByteDance, Alibaba, Temu-owner PDD Holdings, Tencent, Baidu, Kuaishou, Meituan and Xiaomi, according to a new ad forecast from WPP Media. In 2025, the top five advertisers globally are all tech firms and two are Chinese: Google, Meta, ByteDance, Amazon and Alibaba. In 2011, the top five advertisers globally were mostly U.S. publishers: Google, Viacom and CBS, News Corp and Fox, Comcast and Disney. Catch up quick: The growth of China's economy and middle class over the past decade laid the foundation for the country's rapid ad expansion. But its mobile-first internet culture accelerated its dominance. Chinese tech firms have been innovating for the smartphone "to an even greater and faster degree than in other markets which went through a desktop phase first," said Kate Scott-Dawkins, the global president of business intelligence at WPP Media, who authored the report. Zoom in: Over the past several years, Chinese ad sellers have gained dominance by leaning into AI-fueled retail media innovation. This year, China's share of all retail media globally is 44.1%, driven by e-commerce giants like and Alibaba, per WPP Media. But rivals are gaining ground. By 2030, China's share of retail media ad dollars globally is expected to dip to less than 40% as the U.S., U.K. and others scale up, according to Scott-Dawkins. Zoom out: China's ascent in the global advertising hierarchy mirrors a broader shift in tech and economic influence. Chinese platforms are shaping ad innovation with AI-driven commerce and mobile-first experiences. Social and entertainment apps like TikTok have supercharged their ad businesses by expanding their live shopping and e-commerce features. Chinese platforms like TikTok and Temu are rapidly scaling in Western markets. But U.S. tech firms like Google and Meta remain largely blocked from operating in China, limiting the opportunity for reciprocal growth.
Yahoo
39 minutes ago
- Yahoo
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga., June 10, 2025--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: "We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva." The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. "We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month," added Mark Faupel, Guided Therapeutics' CEO. "Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI." About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings. View source version on Contacts Mark FaupelGuided Therapeutics770-242-8723
Yahoo
41 minutes ago
- Yahoo
Starbucks reduces prices on tea-based drinks in China
US coffee giant Starbucks has unveiled a strategic price reduction for its tea-based beverages in its second-largest market, China, aiming to attract customers amid a challenging consumer environment and increasing competition. The coffee chain is set to lower prices by an average of five yuan ($0.70) on a selection of more than a dozen frappuccino, iced tea and tea latte options. The move is designed to appeal to the Chinese market's demand for non-coffee offerings, particularly during the summer season. Starbucks China chief growth officer Tony Yang was quoted by Bloomberg: 'Improved 'non-coffee' product matrix will go side by side with core coffee offerings to better meet the diversified needs of customers.' This decision is a notable shift from the company's usual premium pricing strategy, especially given its promotion on its official WeChat account - a rare marketing approach for the brand in China, according to the news agency. This pricing strategy comes as China is experiencing a deflationary trend in consumer prices, affecting sectors from automotive to fast food. Government data for May 2025 indicates that consumer prices have been in deflationary territory for four consecutive months. By reducing prices, Starbucks is positioning itself to compete more effectively with local tea chains and other beverage providers offering lower-priced options. While Starbucks CEO Brian Niccol is focusing on streamlining the US menu to emphasise coffee, the brand's expansion of tea-based beverages in China is a tailored approach to capture market share in the world's second-largest economy. With the new pricing, Starbucks aims to offer tea drinks starting at 23 yuan - closer to the price points of upscale local tea chains. Local competitors such as Luckin Coffee and Cotti have reduced their pricing, offering drinks for as low as 9.9 or even 8.8 yuan. "Starbucks reduces prices on tea-based drinks in China" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
